Thrivent Financial for Lutherans Raises Holdings in Bristol Myers Squibb Company $BMY

Thrivent Financial for Lutherans lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 172,867 shares of the biopharmaceutical company’s stock after buying an additional 9,407 shares during the period. Thrivent Financial for Lutherans’ holdings in Bristol Myers Squibb were worth $9,232,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of BMY. AM Investment Strategies LLC grew its holdings in shares of Bristol Myers Squibb by 45.5% in the 4th quarter. AM Investment Strategies LLC now owns 7,258 shares of the biopharmaceutical company’s stock worth $391,000 after acquiring an additional 2,269 shares during the period. Avantax Planning Partners Inc. grew its holdings in shares of Bristol Myers Squibb by 7.3% in the 4th quarter. Avantax Planning Partners Inc. now owns 74,548 shares of the biopharmaceutical company’s stock worth $4,021,000 after acquiring an additional 5,070 shares during the period. Cornerstone Wealth Management LLC grew its holdings in shares of Bristol Myers Squibb by 5.9% in the 4th quarter. Cornerstone Wealth Management LLC now owns 34,119 shares of the biopharmaceutical company’s stock worth $1,840,000 after acquiring an additional 1,889 shares during the period. Mesirow Financial Investment Management Inc. grew its holdings in shares of Bristol Myers Squibb by 8.1% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 31,449 shares of the biopharmaceutical company’s stock worth $1,696,000 after acquiring an additional 2,361 shares during the period. Finally, Pinnacle Associates Ltd. grew its holdings in Bristol Myers Squibb by 9.3% during the 4th quarter. Pinnacle Associates Ltd. now owns 118,070 shares of the biopharmaceutical company’s stock valued at $6,369,000 after buying an additional 9,997 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Up 1.6%

Shares of BMY opened at $58.24 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The firm has a market capitalization of $118.92 billion, a P/E ratio of 16.36, a price-to-earnings-growth ratio of 0.16 and a beta of 0.26. The stock’s fifty day simple moving average is $58.53 and its 200 day simple moving average is $55.64. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Barclays assumed coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 target price on the stock. Cantor Fitzgerald increased their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Finally, Piper Sandler restated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.